<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20131009014957N8</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2019-12-04</date_registration>
      <primary_sponsor>Tabriz University of Medical Sciences</primary_sponsor>
      <public_title>Effect of aromatherapy and counseling based on mindfulness on sexual function, anxiety, and serum level of some bio-markers in postmenopausal women</public_title>
      <acronym></acronym>
      <scientific_title>Effect of aromatherapy with essential oil of lavender-bergamot, and counseling based on mindfulness on sexual function, anxiety, and serum level of some bio-markers in postmenopausal women: A randomized controlled trial with factorial design.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-11-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>132</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/41082</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Factorial, Purpose: Supportive, Randomization description: Postmenopausal women aged 50-60 years will be divided into four groups of aromatherapy and routine care, counseling based on Mindfulness-Based Intervention (MBI) and aromatherapy, counseling based on MBI and placebo of aromatherapy, and control group (placebo of aromatherapy and routine care) using the RAS software with four and eight blocks with a 1: 1: 1: 1 allocation ratio and will be stratified based on menopausal years (less than or greater than 5 years). To conceal the allocated intervention, type of counseling intervention (counseling or routine care) will be written on papers and  along with allocated aromas or placebo will be placed in the matte and sealed envelopes numbered from 1 to 132 based on random sequence generated by a non-researcher. The first envelope will be given to the first eligible person and will be continued until the completion of sampling.
The participant, researcher and statistical analyst will not be aware of the contents of the package (allocation concealment). In this study, after the random allocation of the individual to the study group, the researcher and participant blindness would not be possible in terms of counseling,, Blinding description: In this study, outcome assessor and statistical analyst will be kept blind to the specific study groups. So that the combined aroma and its placebo will be poured into identical dark containers and identified only by random code of study. The outcome assessor and the statistical analyst will not be present at the consultation sessions. Questionnaires will not specify the type of intervention and only random code will be written. Also in the statistical software, only the code of the participants and the group number will be written.</study_design>
      <phase>3</phase>
      <hc_freetext>Condition 1: Anxiety. Condition 2: Sexual dysfunction. Condition 3: Depression. Condition 4: Serum levels of some bio-markers. Condition 5: Menopausal symptoms. Condition 6: Sleep quality.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: Mindfulness consulting along with placebo of aroma. Mindfulness in-person counseling will be held once per week for eight weeks through the 45-60 minute sessions in a native language. The number of participants in each meeting will be at least eight and up to twelve. The last 15 minutes will be devoted to question and answer. Aroma placebo (probylene glycol) will be rubbed 2 to 3 drops, 2-3 times a day for 8 weeks. The placebo will be made by Goldaru Pharmaceutical Company and packed in 30 ml dark glass. Intervention 2: Intervention group 2: ََAromatherapy with essential oil of lavender-bergamot along with routine care. Lavender-bergamot essential oil will be applied 3 times daily, 2-3 drops each time for 8 weeks on the forearm. The composition of the essential oils will be in the form of 5% lavender and 0.4% bergamot essential oils. The pure essential oils will be provided by the Goldaru Pharmaceutical Company. The analysis of essential oils, blending of them with the desired concentration will be carried out in the Faculty of Pharmacy and will be packed in 30 ml dark glass.Routine care will be carried out in accordance with the Ministry's approved protocol. Intervention 3: Intervention group 3:  Aromatherapy with essential oil of lavender-bergamot along with Mindfulness consulting. Lavender-bergamot essential oil will be applied 3 times daily, 2-3 drops each time for 8 weeks on the forearm. The composition of the essential oils will be in the form of 5% lavender and 0.4% bergamot essential oils. The pure essential oils will be provided by the Goldaru Pharmaceutical Company. The analysis of essential oils, blending of them with the desired concentration will be carried out in the Faculty of Pharmacy and will be packed in 30 ml dark glass. Mindfulness in-person counseling will be held once per week for eight weeks through the 45-60 minute sessions in a native language. The number of participants in each meeting will be at least eight and up to twelve. The last 15 minutes will be devoted to question and answer. Intervention 4: Control group: Placebo of aroma along with routine care. Aroma placebo (probylene glycol) will be rubbed 2 to 3 drops, 2-3 times a day for 8 weeks. The placebo will be made by Goldaru Pharmaceutical Company and packed in 30 ml dark glass. Routine care will be carried out in accordance with the Ministry's approved protocol.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Requested data will be provided to researchers for statistical analysis of the submitted proposal (meta-analysis).

When:
ُStarting immediately after publication

To whom:
Data will be available to researchers as well as to journals

Conditions:
The data will be available to researchers upon request and submission of a proposal to perform meta-analysis using IPD data after being unidentified. Also, in exceptional cases, data will be made available to journals for checking

Where to obtain:
Refer to the email address (farshbafa@tbzmed.ac.ir)

How to obtain:
The requests will be sent by email and data will be available within a week

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Azizeh Farshbaf-Khalili</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Physical Medicine and Rehabilitation Research Center, Street, Ground Floor, Imam Reza Hospital,  Golgasht Street</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166614766</zip>
        <telephone>+98 41 3336 1928</telephone>
        <email>farshbafa@tbzmed.ac.ir</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Azizeh Farshbaf-Khalili</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Physical Medicine and Rehabilitation Research Center,  Ground Floor, Imam Reza Hospital, Golgasht Street</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166614766</zip>
        <telephone>+98 41 3336 1928</telephone>
        <email>farshbafa@tbzmed.ac.ir</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Willingness to participate in the study
Postmenopausal women  between the ages of 50-60
Having read and write literacy
The Female Sexual Function Score less than 28
Having mild to moderate anxiety based on Beck Anxiety Scale
Having sex in the family limit with her permanent spouse
Having only one wife for the man
Natural menopause
Obtaining a score of 15-42 on the Greene scale
Having a score of 5 and higher in The Pittsburgh Sleep Quality Index (PSQI)</inclusion_criteria>
      <agemin>50 years</agemin>
      <agemax>60 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Known physical and mental illnesses based on person's self statement (depression, diabetes, cardiovascular disease, olfactory sensations, mental disability, diabetes)
Drugs affecting sex (sildenafil, antidepressants, antihistamines, diazepines, barbiturates, amphetamines, antihypertensive drugs, cocaine, thiazide diuretics, narcotics
Use of herbal ingredients to increase sexual desire in men or women (ginseng, cinnamon, ginger, etc.) and alergy to any herbal medicine
Addiction to the habitual consumption of alcohol and tobacco by women
Participate in other similar studies
Occurrence of an misadventure within 3 months prior  of study (death or acute illness of close relatives)
Disorder in the sense of smell according to person's self and other nasal disorders (fracture, aberration, rhinitis)
Use of hormotherapy at last 6 month</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>F41</hc_code>
      <hc_code>F52</hc_code>
      <hc_code>F32</hc_code>
      <hc_code></hc_code>
      <hc_code>N95</hc_code>
      <hc_code>G47</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other anxiety disorders</hc_keyword>
      <hc_keyword>Sexual dysfunction not due to a substance or known physiological condition</hc_keyword>
      <hc_keyword>Major depressive disorder, single episode</hc_keyword>
      <hc_keyword></hc_keyword>
      <hc_keyword>Menopausal and other perimenopausal disorders</hc_keyword>
      <hc_keyword>Sleep disorders</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: Mindfulness consulting along with placebo of aroma. Mindfulness in-person counseling will be held once per week for eight weeks through the 45-60 minute sessions in a native language. The number of participants in each meeting will be at least eight and up to twelve. The last 15 minutes will be devoted to question and answer. Aroma placebo (probylene glycol) will be rubbed 2 to 3 drops, 2-3 times a day for 8 weeks. The placebo will be made by Goldaru Pharmaceutical Company and packed in 30 ml dark glass.</i_keyword>
      <i_keyword>Intervention group 2: ََAromatherapy with essential oil of lavender-bergamot along with routine care. Lavender-bergamot essential oil will be applied 3 times daily, 2-3 drops each time for 8 weeks on the forearm. The composition of the essential oils will be in the form of 5% lavender and 0.4% bergamot essential oils. The pure essential oils will be provided by the Goldaru Pharmaceutical Company. The analysis of essential oils, blending of them with the desired concentration will be carried out in the Faculty of Pharmacy and will be packed in 30 ml dark glass.Routine care will be carried out in accordance with the Ministry's approved protocol.</i_keyword>
      <i_keyword>Intervention group 3:  Aromatherapy with essential oil of lavender-bergamot along with Mindfulness consulting. Lavender-bergamot essential oil will be applied 3 times daily, 2-3 drops each time for 8 weeks on the forearm. The composition of the essential oils will be in the form of 5% lavender and 0.4% bergamot essential oils. The pure essential oils will be provided by the Goldaru Pharmaceutical Company. The analysis of essential oils, blending of them with the desired concentration will be carried out in the Faculty of Pharmacy and will be packed in 30 ml dark glass. Mindfulness in-person counseling will be held once per week for eight weeks through the 45-60 minute sessions in a native language. The number of participants in each meeting will be at least eight and up to twelve. The last 15 minutes will be devoted to question and answer.</i_keyword>
      <i_keyword>Control group: Placebo of aroma along with routine care. Aroma placebo (probylene glycol) will be rubbed 2 to 3 drops, 2-3 times a day for 8 weeks. The placebo will be made by Goldaru Pharmaceutical Company and packed in 30 ml dark glass. Routine care will be carried out in accordance with the Ministry's approved protocol.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Anxiety score in Beck Anxiety Inventory. Timepoint: At baseline and 8 weeks after intervention. Method of measurement: Beck Anxiety Inventory.</prim_outcome>
      <prim_outcome>Sexual function score in Female Sexual Function Index. Timepoint: At baseline and 8 weeks after intervention. Method of measurement: Female Sexual Function Index.</prim_outcome>
      <prim_outcome>Serum level of cortisol. Timepoint: At baseline and immediately after intervention. Method of measurement: Elisa method by ELISA kits.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Depression score using  Beck Depression Inventory. Timepoint: At baseline and 8 weeks after intervention. Method of measurement: Beck Depression Inventory.</sec_outcome>
      <sec_outcome>Serum level of malondialdehyde. Timepoint: َAt baseline and immediately after intervention. Method of measurement: By spectrophotometric method based on reaction with thiobarbituric acid.</sec_outcome>
      <sec_outcome>Serum level of high-sensitivity C-Reactive Protein. Timepoint: َAt baseline and immediately after intervention. Method of measurement: Complex-based turbidometry based on the reaction between high-sensitivity C-Reactive Protein and specific antiserum.</sec_outcome>
      <sec_outcome>Serum level of Total Antioxidant Capacity. Timepoint: َAt baseline and immediately after intervention. Method of measurement: By Autoanalyzer Abbott (Alcyon 300) using Randox kit.</sec_outcome>
      <sec_outcome>Frequency of adverse events. Timepoint: While intervention. Method of measurement: Adverse events checklist.</sec_outcome>
      <sec_outcome>Menopausal symptom score using  Greene climacteric scale. Timepoint: At baseline and 8 weeks after intervention. Method of measurement: Greene Climacteric Scale.</sec_outcome>
      <sec_outcome>The score of Pittsburgh Sleep Quality Index (PSQI). Timepoint: At baseline and 8 weeks after intervention. Method of measurement: Pittsburgh Sleep Quality Index (PSQI).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tabriz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-10-14</approval_date>
        <contact_name>Ethics Committee of Tabriz University of Medical Sciences</contact_name>
        <contact_address>Research Department., Third Floor., Central Construction Number 2., Tabriz University of Medical Sciences., Golgasht Street., Azadi Avenue Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
